11:52 AM
 | 
Jun 08, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 15 evaluable patients with advanced non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that once-daily 200 mg oral bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >